Am J Transplant, Volume 21, Suppl 3 Archives - Page 54 of 139 - ATC Abstracts

2021 American Transplant Congress
Early Stent Removal in Kidney Transplant Recipients – A Quality Improvement Project
V. Rohan, N. Pilch, M. Altiti, S. Nadig, A. Lin, D. DuBay, P. Baliga
Surgery, Medical University of South Carolina, Charleston, SC
*Purpose: Ureteric Stent placement is a is common practice at the time of kidney transplantation to reduce the incidence and severity of Major Urological Complications…
2021 American Transplant Congress
Kidney Transplant Rejection Can Be Diagnosed or Even Predicted by Tracking Donor Reactive T Cell Clones in Post-transplant Samples
Y. Sambandam¹, M. Kandpal¹, J. He¹, X. Huang¹, T. S. Taylor¹, A. A. Shetty², J. M. Mathew¹, J. R. Leventhal¹
¹Surgery-Comprehensive Transplant Center, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Medicine, Nephrology Division, Northwestern University Feinberg School of Medicine, Chicago, IL
*Purpose: To test if kidney transplant (KTx) rejection can be diagnosed by monitoring for donor reactive T-cell (DRTC) clones in post-transplant (post-tx) biopsy and non-invasively…
2021 American Transplant Congress
Therapeutic Response of Late Clinical Cell Mediated Rejection is Modeled by Chronicity Changes
I. Melgarejo¹, V. Visnawathan², A. Sharma¹, P. Sood¹, C. Puttarajappa¹, C. Wu¹, N. Shah¹, M. Molinari¹, S. Hariharan¹, R. Mehta¹
¹Starzl Transplant Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, ²Department of Medicine, Renal-Electrolyte Division, University of Pittsburgh Medical Center, Pittsburgh, PA
*Purpose: Although there is a tendency to treat late clinical TCMR, the responsiveness to steroids is unclear.*Methods: Among kidney transplant recipients, transplanted between Jan 2013…
2021 American Transplant Congress
Dd-cfdna Can Guide Safe Reintroduction of Immunosuppression in Kidney Transplant Recipients with Covid-19
J. Miles¹, J. Leonard², V. Tatapudi², M. Fei¹, R. Montgomery², N. M. Ali²
¹CareDx, Brisbane, CA, ²Transplant Institute, NYU Langone Health, New York, NY
*Purpose: COVID-19 infection is associated with 25% mortality in kidney transplant recipients (KTRs). Reduction of anti-metabolite immunosuppressants during the acute COVID-19 illness is a common…
2021 American Transplant Congress
Increased T Cell Cross-dressing in Accepted Kidney Allografts
Q. Yuan¹, S. Hong², E. Szuter², I. Rosales², Y. Zhao², B. Gonzalez-Nolasco², G. Benichou², P. Russell², J. Madsen², R. Colvin², A. Alessandrini²
¹Massachusetts General Hospital/Chinese PLA General Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, MA
*Purpose: Kidney allografts transplanted across certain mouse strain combinations (e.g. DBA/2 to B6) develop tolerance while other combinations do not (e.g. B6 to DBA/2). We…
2021 American Transplant Congress
Single-Dose Basiliximab Induction Therapy in Low-Immunologic Risk Kidney Transplant Recipients
A. Hutchins, J. Schoen, J. S. McMullen
Pharmacy, Nebraska Medicine, Omaha, NE
*Purpose: The purpose of this study is to examine the outcomes associated with single-dose basiliximab in low-immunologic risk kidney transplant recipients following a revision to…
2021 American Transplant Congress
Cost Effectiveness Analysis Comparing Treatments of Biliary Strictures in Pediatric Liver Transplant Patients
B. Whitehead¹, C. Lemoine², R. Superina², J. Green³, S. Mohammad¹
¹Division of Gastroenterology, Hepatology and Nutrition, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ²Division of Transplant Surgery, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ³Division of Interventional Radiology, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL
*Purpose: Biliary strictures are associated with significant morbidity after pediatric liver transplantation. There are two main treatment options which are percutaneous transhepatic cholangiography (PTC) and…
2021 American Transplant Congress
Extracellular Matrix Injury of Kidney Allografts in Antibody-mediated Rejection
S. Clotet Freixas¹, C. McEvoy¹, I. Batruch², C. Pastrello³, M. Kotlyar³, J. Van¹, M. Arambewela¹, A. Boshart¹, S. Farkona¹, Y. Niu³, Y. Li¹, O. Famure¹, A. Bozovic⁴, V. Kulasingam⁴, P. Chen¹, J. S. Kim¹, E. Chan⁵, S. Moshkelgosha¹, S. A. Rahman⁶, J. Das⁶, T. Martinu¹, S. Juvet¹, I. Jurisica³, A. Chruscinski¹, R. John¹, A. Konvalinka¹
¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Department of Laboratory Medicine and Pathobiology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada, ³Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁴Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada, ⁵Department of Medicine, Division of Nephrology, University Health Network, Toronto, ON, Canada, ⁶Center for Systems Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA
*Purpose: Antibody-mediated rejection (AMR) accounts for >50% of kidney graft losses. AMR is caused by donor-specific antibodies (DSA) against HLA and non-HLA antigens in glomeruli…
2021 American Transplant Congress
Superior Post-transplant Clinical Outcomes Using Portable Normothermic Perfusion and Assessment with the Organ Care System (ocs) Liver System: 1-year Outcomes of the Ocs Liver Protect Randomized Controlled Trial
J. Markmann¹, M. Abouljoud², M. Ghobrial³, C. Bhati⁴, S. Pelletier⁵, J. Magliocca⁶, T. Pruett⁷, A. Lu⁸, M. Rizzari⁹, S. Ottmann¹⁰, T. Klair¹¹, C. Eymard¹², G. Roll¹³, G. Reyes¹⁴, S. Black¹⁵, S. Florman¹⁶, S. Mirani¹⁷, C. Marsh¹⁸, G. Schnickel¹⁹, M. Kinkhabwala²⁰, A. Demetris²¹, H. Yeh²², P. Vagefi²³, M. MacConmara²³
¹MGH, Boston, MA, ²Henry Ford, Detroit, MI, ³Houston Methodist, Houston, TX, ⁴Virginia Commonwealth, Richmond, VA, ⁵UVA, Charlottesville, VA, ⁶Emory, Atlanta, GA, ⁷U. Minnesota, Minneapolis, MN, ⁸Tampa General, Tampa, FL, ⁹Henry Ford, Detriot, MI, ¹⁰Johns Hopkins, Baltimore, MD, ¹¹University of Texas HSC, San Antonio, TX, ¹²University of Tennessee HSC, Memphis, TN, ¹³UCSF, San Francisco, CA, ¹⁴U. Washington, Seattle, WA, ¹⁵Ohio State, Columbus, OH, ¹⁶Mt. Sinai, New York, NY, ¹⁷U. Nebraska, Omaha, NE, ¹⁸Scripps Clinic, San Diego, CA, ¹⁹U. San Diego, San Diego, CA, ²⁰Montefiore, New York, MA, ²¹UPMC, Pittsburgh, PA, ²²Massachusetts General Hospital, Boston, MA, ²³UT Southwestern, Dallas, TX
*Purpose: The OCS Liver PROTECT Trial was the first U.S. randomized controlled trial for liver perfusion and was designed to evaluate the impact of portable…
2021 American Transplant Congress
Prediction of Renal Allograft Tolerance by Machine Learning
Q. Fu¹, K. Deng², H. Yang¹, S. Deng¹, J. F. Markmann²
¹Organ Transplantation Center, Sichuan Provincial People's Hospital, University of Electronic Sciences and Technology of China, Chengdu, China, ²Center for Transplantation Sciences, MGH, Boston, MA
*Purpose: An ideal goal of transplantation is to withdraw or minimize immunosuppressants via the induction of tolerance to overcome drug toxicity, prolong allograft survival, and…